Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Sarcoma 1Carcinoma, Transitional Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Nivolumab 5Magnetic Resonance Spectroscopy 5Specimen Handling 4pembrolizumab 2Ipilimumab 2Immunoglobulin G 2tislelizumab 1temsirolimus 1spartalizumab 1sargramostim 1regorafenib 1pemigatinib 1eribulin 1cabozantinib 1brivanib 1avelumab 1X-Rays 1Valproic Acid 1Sirolimus 1Radiosurgery 1Mifepristone 1Fluorodeoxyglucose F18 1FAPI-46 1Docetaxel 1Disulfides 1Cyclophosphamide 1Cryosurgery 1Colony-Stimulating Factors 1Clinical Trials, Phase II as Topic 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × brivanib × Sarcoma × Clear all
NCT00633789 2015-10-09

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Bristol-Myers Squibb

Phase 2 Completed
597 enrolled
GastrointestinalGenitourinarySarcoma

Adenocarcinoma Of Esophagus, Carcinoma, Transitional Cell, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡